BACKGROUND: Little is known about the long-term antibody response to the 2009-H1N1 vaccine in solid organ transplant recipients (SOTR) and its clinical repercussion on the efficacy of following 2010-2011 influenza vaccine. METHODS: We performed a multicenter prospective study in SOTR receiving one dose of the nonadjuvant 2010-2011 seasonal influenza vaccine and determined the immunological response at 5 weeks after vaccination. RESULTS: One hundred SOTR were included. Long-term antibody titers to the previous vaccine were only detected in one third of the patients. Patients with baseline titers had significantly higher seroprotection for the 2009-H1N1 strain (100% vs. 73%, relative risks [RR] 1.37, 95% confidence intervals [CI] 1.19-1.57; P=0.006), for H3N2 strain (100% vs. 62.2%, RR 1.61, 95% CI 1.36-1.90; P=0.005), and for B strain (100% vs. 69%; P=0.02). The seroconversion rate in patients with baseline titers was 90.9% vs. 73% (RR 2.97, 95% CI 0.75-11.74; P=0.07) for the 2009-H1N1 strain, 92.2% vs. 62.2% (RR 5.29, 95% CI 0.8-35.7; P=0.02) for the H3N2 strain, and 58.3% vs. 69% (P=0.45) for the B strain. CONCLUSIONS: SOTR response to the 2010-2011 influenza vaccine was not optimal. The response was related to baseline titers; however, most of the patients did not exhibit detectable antibodies at vaccination lacking long-term response. New strategies are necessary to improve vaccination efficacy.
BACKGROUND: Little is known about the long-term antibody response to the 2009-H1N1 vaccine in solid organ transplant recipients (SOTR) and its clinical repercussion on the efficacy of following 2010-2011 influenza vaccine. METHODS: We performed a multicenter prospective study in SOTR receiving one dose of the nonadjuvant 2010-2011 seasonal influenza vaccine and determined the immunological response at 5 weeks after vaccination. RESULTS: One hundred SOTR were included. Long-term antibody titers to the previous vaccine were only detected in one third of the patients. Patients with baseline titers had significantly higher seroprotection for the 2009-H1N1 strain (100% vs. 73%, relative risks [RR] 1.37, 95% confidence intervals [CI] 1.19-1.57; P=0.006), for H3N2 strain (100% vs. 62.2%, RR 1.61, 95% CI 1.36-1.90; P=0.005), and for B strain (100% vs. 69%; P=0.02). The seroconversion rate in patients with baseline titers was 90.9% vs. 73% (RR 2.97, 95% CI 0.75-11.74; P=0.07) for the 2009-H1N1 strain, 92.2% vs. 62.2% (RR 5.29, 95% CI 0.8-35.7; P=0.02) for the H3N2 strain, and 58.3% vs. 69% (P=0.45) for the B strain. CONCLUSIONS: SOTR response to the 2010-2011 influenza vaccine was not optimal. The response was related to baseline titers; however, most of the patients did not exhibit detectable antibodies at vaccination lacking long-term response. New strategies are necessary to improve vaccination efficacy.
Authors: Michelle Cowan; W James Chon; Amishi Desai; Sarah Andrews; Yaohui Bai; Vic Veguilla; Jacqueline M Katz; Michelle A Josephson; Patrick C Wilson; Roger Sciammas; Anita S Chong Journal: Transplantation Date: 2014-04-27 Impact factor: 4.939
Authors: M S Camacho-Lovillo; A Bulnes-Ramos; W Goycochea-Valdivia; L Fernández-Silveira; E Núñez-Cuadros; O Neth; P Pérez-Romero Journal: Pediatr Rheumatol Online J Date: 2017-08-07 Impact factor: 3.054
Authors: Juliana Martinez-Atienza; Clara Rosso-Fernández; Cristina Roca; Teresa A Aydillo; Joan Gavaldà; Asunción Moreno; Jose M Montejo; Julian Torre-Cisneros; M Carmen Fariñas; Jesus Fortun; Nuria Sabé; Patricia Muñoz; Marino Blanes-Julia; Alejandro Suárez-Benjumea; Francisco López-Medrano; Pilar Pérez-Romero; Elisa Cordero Journal: Trials Date: 2014-08-28 Impact factor: 2.279
Authors: O Manuel; F López-Medrano; L Keiser; T Welte; J Carratalà; E Cordero; H H Hirsch Journal: Clin Microbiol Infect Date: 2014-09 Impact factor: 8.067